Evolution of implantable and insertable drug delivery systems.

The paper describes the development of implantable and insertable drug delivery systems (IDDS) from their early stage in the 1960s until the current stage in the 2010s. It gives a detailed summary of non-degradable and biodegradable systems and their applications in different areas such as vascular disease treatment, birth control, cancer treatment, and eye disease treatment. It also describes the development of various implantable pump systems and some other atypical IDDS, the challenges and the future of IDDS.

[1]  F. Theeuwes,et al.  Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations , 1976, Annals of Biomedical Engineering.

[2]  Giuseppe Perale,et al.  Bioresorbable polymer coated drug eluting stent: a model study. , 2012, Molecular pharmaceutics.

[3]  T. Emrick,et al.  Aliphatic polyester terpolymers for stent coating and drug elution: Effect of polymer composition on drug solubility and release , 2009, Drug delivery.

[4]  G. Stone,et al.  SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. , 2009, American heart journal.

[5]  R. Gurny,et al.  Intraocular implants for extended drug delivery: therapeutic applications. , 2006, Advanced drug delivery reviews.

[6]  J. Ardisson,et al.  Study of mesoporous silica/magnetite systems in drug controlled release , 2009, Journal of materials science. Materials in medicine.

[7]  Phyllis Gardner,et al.  Microfabricated nanochannel implantable drug delivery devices: trends, limitations and possibilities , 2006, Expert opinion on drug delivery.

[8]  Kinam Park.  Dual drug-eluting stent. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Ellis Meng,et al.  Micro- and nano-fabricated implantable drug-delivery systems. , 2012, Therapeutic delivery.

[10]  黄亚明,et al.  RxList , 2012 .

[11]  Allan S. Hoffman,et al.  The origins and evolution of "controlled" drug delivery systems. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[12]  M. Robinson,et al.  Ocular Implants For Drug Delivery , 2008 .

[13]  M. Cima,et al.  A controlled-release microchip , 1999, Nature.

[14]  Marco Pizzi,et al.  Fabrication of Self Assembled Micro Reservoirs for Controlled Drug Release , 2004, Biomedical microdevices.

[15]  J. Guillet,et al.  Drug Delivery Systems , 1995 .

[16]  Robert Langer,et al.  Small-scale systems for in vivo drug delivery , 2003, Nature Biotechnology.

[17]  Patrick W Serruys,et al.  Bioresorbable Scaffold: The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization? , 2011, Circulation.

[18]  E. Krames.  Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. , 1996, Journal of pain and symptom management.

[19]  D. Lewis,et al.  Fibrous Polymers for the Delivery of Contraceptive Steroids to the Female Reproductive Tract , 1981 .

[20]  Kinam Park,et al.  Mechanisms of controlled drug release from drug-eluting stents. , 2006, Advanced drug delivery reviews.

[21]  D. Crommelin,et al.  Controlled release of bioactive agents from lactide/glycolide polymers , 1990 .

[22]  J. Siepmann,et al.  Ethanol-resistant polymeric film coatings for controlled drug delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[23]  R. Langer,et al.  Polymers for the sustained release of proteins and other macromolecules , 1976, Nature.

[24]  Marc D Feldman,et al.  Coronary stents: a materials perspective. , 2007, Biomaterials.

[25]  J. Miller,et al.  Implantable Systems for Delivery of Insect Growth Regulators to Livestock.II , 1981 .

[26]  R. Virmani,et al.  A review of current devices and a look at new technology: drug-eluting stents , 2009, Expert review of medical devices.

[27]  John A Ormiston,et al.  Bioabsorbable coronary stents. , 2009, Circulation. Cardiovascular interventions.

[28]  R. Siegel,et al.  BioMEMS devices for drug delivery , 2009, IEEE Engineering in Medicine and Biology Magazine.

[29]  F Theeuwes,et al.  Elementary osmotic pump. , 1975, Journal of pharmaceutical sciences.

[30]  C. Stevenson,et al.  An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[31]  R. Wheeler,et al.  Release of Drugs from IUDs Using an Ethylene Vinyl Acetate Matrix , 1981 .

[32]  Long-Term Controlled Delivery of Therapeutic Agents by the Osmotically Driven DUROS® Implant , 2008 .

[33]  Donald R Paul,et al.  Diffusional release of a solute from a polymer matrix , 1976 .

[34]  D. Untereker,et al.  Degradability of Polymers for Implantable Biomedical Devices , 2009, International journal of molecular sciences.

[35]  Tzu-Wei Wang,et al.  A novel biomagnetic nanoparticle based on hydroxyapatite , 2007 .

[36]  Patrick W Serruys,et al.  The ABSORB bioresorbable vascular scaffold: an evolution or revolution in interventional cardiology? , 2012, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[37]  R. Langer,et al.  Experimental Approaches for Achieving Both Zero-Order and Modulated Controlled Release from Polymer Matrix Systems , 1981 .

[38]  R. Carbonell,et al.  Drug Delivery Technologies: The Way Forward in the New Decade , 2009 .

[39]  P. Serruys,et al.  Advances in stent drug delivery: the future is in bioabsorbable stents , 2009, Expert opinion on drug delivery.

[40]  Willi Paul,et al.  Ceramic Drug Delivery: A Perspective , 2003, Journal of biomaterials applications.

[41]  N. Tabary,et al.  Comparative study of vascular prostheses coated with polycyclodextrins for controlled ciprofloxacin release. , 2012, Carbohydrate polymers.

[42]  R. Rapoza,et al.  Design principles and performance of bioresorbable polymeric vascular scaffolds. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[43]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.

[44]  A. Fassihi,et al.  Implantable Controlled Release Drug Delivery Systems: A Review , 1991 .

[45]  J. Folkman,et al.  THE USE OF SILICONE RUBBER AS A CARRIER FOR PROLONGED DRUG THERAPY. , 1964, The Journal of surgical research.

[46]  H. Gabelnick,et al.  Contraceptive devices: intravaginal and intrauterine delivery systems , 2008, Expert review of medical devices.

[47]  S. Hossainy,et al.  Modeling of degradation and drug release from a biodegradable stent coating. , 2007, Journal of biomedical materials research. Part A.

[48]  R. Schmidt,et al.  Cancer therapy-associated CNS neuropathology: an update and review of the literature , 2006, Acta Neuropathologica.

[49]  T. Higuchi.  MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES. , 1963, Journal of pharmaceutical sciences.

[50]  G. Steil,et al.  Evaluation of the Effect of Gain on the Meal Response of an Automated Closed-Loop Insulin Delivery System , 2006, Diabetes.

[51]  C. McCormick,et al.  Controlled Release of Metribuzin, 2,4-D, and Model Aromatic Amines from Polysaccharides and Poly(Vinyl Alcohol) , 1981 .

[52]  J. Margolis,et al.  Hideo Tamai memorial , 2009 .

[53]  Raimund Erbel,et al.  Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial , 2013, The Lancet.

[54]  S. Hossainy,et al.  A mathematical model for predicting drug release from a biodurable drug-eluting stent coating. , 2008, Journal of biomedical materials research. Part A.

[55]  A. Dash,et al.  Therapeutic applications of implantable drug delivery systems. , 1998, Journal of pharmacological and toxicological methods.

[56]  P. Serruys,et al.  Future Directions of Drug‐Eluting Stents , 2009 .

[57]  K. Bhise,et al.  Biodegradable polymers: Which, when and why? , 2007 .

[58]  F. Martin,et al.  Microfabricated Drug Delivery Systems: Concepts to Improve Clinical Benefit , 2001 .

[59]  J. Resar,et al.  Drug‐eluting versus third‐generation bare metal stents: The US strategy , 2005, International journal of cardiovascular interventions.